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Mature natural killer (NK) cell neoplasms are classified by the World Health Organization into NK/T cell lymphoma,
nasal type (NKTCL), aggressive NK-cell leukemia (ANKCL) and chronic lymphoproliferative disorders of NK-cells, the
latter being considered provisionally. NKTCL and ANKCL are rare diseases, with higher prevalence in Asia, Central
and South America. Most NKTCL present extranodal, as a destructive tumor affecting the nose and upper
aerodigestive tract (nasal NKTCL) or any organ or tissue (extranasal NKTCL) whereas ANKCL manifests as a systemic
disease with multiorgan involvement and naturally evolutes to death in a few weeks. The histopathological
hallmark of these aggressive NK-cell tumors is a polymorphic neoplastic infiltrate with angiocentricity,
angiodestruction and tissue necrosis. The tumor cells have cytoplasmatic azurophilic granules and usually show a
CD45+bright, CD2+, sCD3-, cytCD3epsilon+, CD56+bright, CD16−/+, cytotoxic granules molecules+ phenotype. T-cell
receptor genes are in germ-line configuration. Epstein-Barr virus (EBV) -encoded membrane proteins and early
region EBV RNA are usually detected on lymphoma cells, with a pattern suggestive of a latent viral infection type II.
Complex chromosomal abnormalities are frequent and loss of chromosomes 6q, 11q, 13q, and 17p are recurrent
aberrations. The rarity of the NK-cell tumors limits our ability to standardize the procedures for the diagnosis and
clinical management and efforts should be made to encourage multi-institutional registries.
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As neoplasias de células natural killer (NK) maduras foram classificadas pela Organização Mundial de Saúde em três
entidades: o linfoma de células NK/T tipo nasal (NKTCL), a leucemia agressiva de células NK (ANKCL) e as doenças
linfoproliferativas crónicas de células NK, estas últimas consideradas uma entidade provisória. Os NKTCL e a ANKCL
são doenças raras, mais prevalentes na Ásia, na América Central e na América do Sul. A maioria dos NKTCL tem
uma apresentação extra-ganglionar, na forma de tumor destrutivo que atinge o nariz e o trato aerodigestivo alto
(forma nasal) ou qualquer órgão ou tecido (forma extranasal). A ANKCL manifesta-se como uma doença sistémica
que evolui para a morte em poucas semanas. Do ponto de vista histopatológico, estas neoplasias caraterizam-se
por um infiltrado polimórfico, com angiocentricidade, destruição vascular e necrose tecidular. As células tumorais
têm grânulos azurófilos no citoplasma e o seu imunofenótipo (CD45+forte, CD2+, sCD3-, cytCD3epsilon+, CD56+forte,
CD16−/+, proteínas dos grânulos citotóxicos+) é caraterístico. Os genes que codificam para o recetor das células T
estão em configuração nativa. As células tumorais expressam geralmente proteínas da membrana e ARN do vírus
Epstein Barr, com um padrão sugestivo de uma infecção vírica latente tipo II. As alterações cromossómicas são
(Continued on next page)Correspondence: mmc.lima@clix.pt
1Department of Hematology, Laboratory of Cytometry, Hospital de Santo
António (HSA), Centro Hospitalar do Porto (CHP), Rua D. Manuel II, s/n,
4099-001, Porto, Portugal
2Multidisciplinary Unit for Biomedical Investigation (UMIB/ICBAS/UP), Porto,
Portugal
© 2013 Lima; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lima Orphanet Journal of Rare Diseases 2013, 8:95 Page 2 of 10
http://www.ojrd.com/content/8/1/95(Continued from previous page)
complexas, e algumas, como deleções nos braços longos dos cromossomas 6, 11 e 13 e do braço curto do
cromossoma 17, ocorrem de forma recorrente. A raridade dos tumores de células NK limita a nossa capacidade
para uniformizar os procedimentos de diagnóstico e a abordagem clínica, sendo necessário desenvolver esforços
para promover os registos multicêntricos.
Palavras-chave: Neoplasias de células NK, Linfomas de células NK, tipo nasal, Leucemia agressiva de células NK, CD56Introduction
Lymphoproliferative disorders of natural killer (NK) cells
are rare diseases which account for less than 5% of all
lymphoid neoplasms and comprise different clinical en-
tities [1-17].
The World Health Organization (WHO) classification of
tumors of hematopoietic and lymphoid tissues, updated in
2008, has made advances in their classification. Accordingly,
three disease conditions originating from mature NK-cells
were proposed based on their distinct clinical and patho-
logical features [18]. These include two aggressive mature
NK-cell neoplasms – extranodal NK/T cell lymphoma,
nasal type (NKTCL) [19], and aggressive NK-cell leukemia
(ANKCL) [20] – and one provisional entity – chronic
lymphoproliferative disorders of NK-cells (CLPD-NK) [21]
(Table 1). The first two entities are indexed individually in
the 10th revision of the International Classification of Dis-
eases (ICD-10) [22] and in the 3rd edition of the ICD for
Oncology (ICD-O-3) [23], as well as in Orphanet databases
[24]. In addition, two diseases were proposed in the past as
originating from NK-cell precursors, based mainly on the
blastic appearance and the CD56+ immature immunophe-
notype of the neoplastic cells. The first, NK-cell lympho-
blastic leukemia / lymphoma [25], in fact comprise an
heterogeneous group of immature disorders originating
from NK-, T- and/or myeloid cell precursors, and is now
being considered in the group of the acute leukemia of am-
biguous lineage; the other, blastic plasmacytoid dendritic
cell neoplasm, previously designed blastic NK-cell lymph-
oma, arises from plasmacytoid dendritic cells and should
no longer be considered a NK-cell malignancy [26].
Nasal type NKTCL, originates in nasal and extranasal or-
gans and tissues and account for the majority of cases, with
only exceptional cases presenting primarily in the lymph
nodes. ANKCL manifests as a systemic disease with
multiorgan failure and rapidly evolutes to death. The diag-
nosis of these aggressive NK-cell neoplasms is often difficult
and requires both clinical suspicion and a differentiated
laboratorial approach based in morphological, immunophe-
notypic and molecular studies.
We review the epidemiology and the clinical and labo-
ratorial criteria for the diagnosis of NKTCL and ANKCL,
with emphasis on tissue histology and on the morpho-
logical, immunophenotypic and genetic features of the neo-
plastic cells.Review
Epidemiology
Both NKTCL and ANKCL are relatively frequent in Asia,
Central and South America, but extremely rare in Europe
and North America [1-17].
Extranodal NK/T-cell lymphoma, nasal type, and ANKCL
are relatively frequent in Central American (e.g. Mexico,
Guatemala), South American (e.g. Argentina, Brazil, Peru,
Chile) and Eastern (e.g. Hong Kong, Japan, Korea) coun-
tries, where they may account for up to 10% of the non
Hodgkin’s lymphoma (NHL), whereas very uncommon in
North America and Europe, where they represent less than
1% of the NHLa [1,2,27-29]. Moreover, in series from the
United States in which the ethnic background was re-
corded, most patients with NKTCL were of Asian or
Hispanic descent [30]. Few epidemiological data is available
in Europe, where its prevalence has been estimated to be
lower than 1–9 cases / 1.000.000 inhabitants.
Aggressive NK-cell neoplasms are almost always asso-
ciated to Epstein Barr Virus (EBV) and similarly to that
occurring in Hodgkin’s lymphoma and nasopharyngeal
carcinoma, the neoplastic NK-cells usually have a type II la-
tency pattern, expression of EBV nuclear antigens (EBNA)
and latent membrane proteins (LMP) being limited to
EBNA-1, LMP-1, and LMP-2 [31]. In Asia, increase in the
risk of developing nasal NKTCL have been described
among crop producers and individuals exposed to pesti-
cides [32], also having an increased risk to develop NHL in
general [33,34].
The International Peripheral T-cell Lymphoma Project
(IPTCLP) group reported a four-fold higher relative fre-
quency of NKTCL among lymphomas in Asian countries
compared to Western countries, ANKCL being rarer than
NKTCL (Table 2). From the 136 cases of NK-cell neo-
plasms analyzed by this group, collected in different centers
from various countries in North America, Europe, and Asia,
only 2 (1.5%) corresponded to ANKCL, as compared to 127
cases of NKTCL, the remaining 7 cases being unclassifiable
according to the WHO schema [35]. Comparatively, based
on the Japanese survey of NK-cell neoplasms diagnosed
from 1994 to 1998 [36], the NK-cell Tumor Study Group
reported on a Japanese series of 172 NK-cell tumors, which
included 22 ANKCL (12.8%) [37]. Few European series of
NKTCL were published to date [38,39] and, in Europe, re-
ports on ANKCL are limited to sporadic cases [40-43].
ble 1 Natural killer cell neoplasms according to the World Health Organization classification of tumors of hematop etic and lymphoid tissues
WHO
ssification, 2008
Disease entities Putative cells
of origin
Orphanet
numbers
Synonyms in the Orphanet data base ICD codes Prevalence
categories
(/1.000.000)
[References]
IC 0 ICD-O-3
K-cell neoplasms Extranodal NK/T-cell
lymphoma (NKTCL),
nasal type
Mature NK-cells 86879 NK/T-cell lymphoma; Nasal T/natural killer-cell
lymphoma; Angiocentric T-cell lymphoma;
Lethal midline granuloma
C 0 9719/3 <1-9 [19,22-24]
Aggressive NK-cell
leukemia (ANKCL)
Mature NK-cells 86873 Aggressive NK-cell leukemia; Aggressive NK-cell
lymphoma; NK-cell LGL leukemia; NK-cell large
granular lymphocyte leukemia
C 7 9948/3 <1-9 [20,22-24]
ovisional entities Chronic lymphoproliferative
disorders of NK-cells
(CLPD-NK)
Mature NK-cells Not available NK-cell LGL leukemia; NK-cell large granular
lymphocyte leukemia (considered together
with ANKCL)
Not a ilable
(C9 )*
Not available
(9831/3)**
Unknown [21-24]
NK-cell lymphoblastic
leukemia / lymphoma
NK-, T- and/or myeloid
precursor cells
Not available Not available Not a ilable Not available Unknown [22-25]
reviations: ICD-10 International Statistical Classification of Diseases and Related Health Problems (formerly designated International Classification for Disease 10th revision, 2010, World Health Organization
ailable in: http://apps.who.int/classifications/icd10/browse/2010/en; accessed in 2 February 2013); ICD-O-3 International Statistical Classification of Diseases an elated Health Problems, for Oncology (formerly
ignated International Classification of Diseases for Oncology, 3rd edition, 2000, World Health Organization (available in: http://www.who.int/classifications/icd aptations/oncology/en/index.html; accessed in 2
ruary 2013); WHO World Health Organization.
stic plasmacytoid dendritic cell neoplasm, also known as CD4+ CD56+ hematodermic neoplasm and previously designed blastic NK-cell lymphoma (Orpha:86 ; ICD-10: C86.4, still referred as blastic NK-cell
phoma; ICD-O: 9727/3) arises from plasmacytoid dendritic cells and should no longer be considered a NK-cell malignancy [26].
onsidering the synonymous list, CLPD-NK, which include chronic NK-cell LGL leukemia cases, are considered together with ANKCL; ** According to the propo of the WHO classification, 2008, CLPD-NK should be
sidered together with T-LGLL in the ICD-O.
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Table 2 Frequencies of NK/T-cell Lymphoma, nasal type, and aggressive NK-cell leukemia in previous published series
Series Origin NKTCL ANKCL NKTCL + ANKCL [References]
NK-cell Tumor Study Group * Asia (Japan) 150 (87.2%) 22 (12.8%) 172 (100%) [37]
Nasal: 123 (82.0%)
Extranasal: 27 (18.0%)
International Peripheral T-Cell
Lymphoma Project (IPTCLP) group**
North America, Europe, and Asia 127 (98.5%) 2 (1.5%) 129 (100%) [35]
Nasal: 92 (72.4%)
Extranasal: 35 (27.6%)
Brazilian group South America (Brazil) 120 (100%) 0 (0%) 120 (100%) [44]
Nasal: 97 (80.8%)
Extranasal: 23 (19.2%)
Intergruppo Italiano Linfomi Europe (Italy) 26 (100%) 0 (0%) 26 (100%) [39]
Nasal: 23 (88.5%)
Extranasal: 3 (11.5%)
All series 423 (94.6%) 25 (5.6%) 447 (100%) NA
Nasal: 335 (79.4%)
Extranasal: 88 (20.6%)
Abbreviations: ANKTCL aggressive NK-cell leukemia, NKTCL NK/T-cell Lymphoma, nasal type, NA not applicable.
* Most of the cases presented in this series were from the Japanese survey of NK-cell neoplasms diagnosed between 1994 and 1998, in which 237
cases were registered: 149 nasal-type NK-cell lymphoma (123 nasal and 26 extranasal), 22 aggressive NK-cell leukemia/lymphoma, 19 chronic NK
lymphocytosis and 57 cases corresponding to diseases that are not considered as originating from mature NK-cells accordingly to the WHO
classification updated in 2008 (11 myeloid/NK-cell precursor acute leukemia, 15 blastic NK-cell lymphoma, 21 precursor NK-cell acute lymphoblastic
leukemia) [36].
** Consecutive cases of peripheral T-cell lymphoma (excluding Mycosis Fungoides and Sezary syndrome) and NK/T-cell lymphoma diagnosed between 1990 and
2002. Total number of cases registered: 1153 (Asia: 464, 40.2%; Europe and North America 689, 59.8%). Total number of NK-cell neoplasms registered: 136 (11.8%)
(Asia: 104, 76.5%; Europe and North America: 32, 23.5%) (NKTCL: 127; ANKCL: 2; unclassified NK-cell neoplasms: 7).
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scribed, the nasal and the extranasal forms, the first being
more frequent in nearly all reported series. In the register
from the Japanese survey, only 18% of the NKTCL were
extranasal [37], a higher percentage of extranasal cases
(28%) being found among the NKTCL reported by the
IPTCLP group [35]; in addition, a Brazilian and an Italian
series of NKTCL included 19% and 12% of extranasal
lymphomas, respectively [39,44] (Table 2).Table 3 Major clinical features of the NK-cell lymphoma, nasa
Clinical features NKTCL (nasal) N
Gender Males > Females
Age (years) 50 – 60
Sites primarily
involved
Nose, paranasal sinuses, orbits
Skin, gastrointe
eyes, soft tissu
tong, other orga
Clinical presentation
Nasal bleeding, nasal obstruction,
palate perforation, mid-facial and/or
upper airway destructive lesions
Prognosis
Early stages (I/II): good
Usually ad
Advanced stages (III/IV): poor
Abbreviations: ANKTCL aggressive NK-cell leukemia, NKTCL NK/T-cell Lymphoma, na
Adapted from [14].Clinical features
Extranodal NK/T cell lymphomas, nasal type
The nasal and extranasal forms of NKTCL differ from
each other from the clinical point of view (Table 3)
[1,10,14,45].
Nasal NK/T cell lymphomas
In contrast to that observed in Occidental countries, where
the majority of the sinonasal lymphomas are B-celll type, and aggressive NK-cell leukemia
KTCL (extranasal) ANKCL
Males > Females Males = Females
50 – 60 30 – 40
stinal tract, salivary glands, lungs,
es, adrenal glands, brain, breast,
ns and tissues; rarely lymph nodes.
Blood, bone marrow, spleen,
liver, lymph nodes
Ulcers, masses
Fever, jaundice, splenomegaly,
hepatomegaly, lymphadenopathy,
cytopenias, hemophagocytic syndrome
vanced stages (III/IV): poor Highly aggressive / fatal
sal type.
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originate from NK-cells. This neoplasm (also known as “le-
thal midline granuloma” or “midline malignant reticulosis”)
commonly affects males and generally manifests as a lo-
calized disease, with mid-facial and/or upper airway de-
structive lesions [1,10,14,45]. Patients with nasal NKTCL
present with nasal signals and symptoms, including mass,
obstruction swelling, or bleeding. The tumor is locally in-
vasive and often infiltrates the surrounding tissues, such
as the nasopharynx, the oropharynx, the palate and the or-
bits; dissemination to other organs may occur in advanced
disease stages.
Extranasal NK/T cell lymphomas
The extranasal form is frequently disseminated at the
time of the diagnosis, most patients having multiple or-
gans and tissues involved, usually without adenopathies
[1,10,14,45]. Patients with extranasal NKTCL often have
more adverse clinical features such as an advanced stage
and poor performance status, and are more likely to
have cytopenias, when compared to patients with nasal
lymphoma [1,10,14]. The tumor may involve any ana-
tomic site at the disease presentation or during disease
progression, including the skin, the gastrointestinal tract,
the testis, the lungs, the eyes, the soft tissues, the adrenal
glands, the brain, the breast and the tongue [1,10,14].
The diagnosis of an extranasal NKTCL requires the ex-
clusion of occult nasal disease, which may require nasal
endoscopy with random biopsies.
Bone marrow involvement at the diagnosis is uncom-
mon in NKTCL, in both nasal (<3.5%) and extranasal
(<7%) cases [4,46]. In contrast, the hemophagocytic syn-
drome is relatively frequent, and often occurs in ad-
vanced disease [47].
Nodal NK-cell lymphomas, nasal type
Although nodal NKTCL are not being considered separ-
ately in the WHO classification, a few cases of NKTCL
presenting primarily in the lymph nodes have been de-
scribed [44,48-52]. Some of these cases were included in
extranodal NKTCL series [44,50] and in series of pa-
tients with cytotoxic lymphomas [51]. For instance, in a
review of 49 Asian cases of CD56+ neoplasms from
which 34 were NKTCL, one had a primary nodal presen-
tation [50] and a Brazilian series of 122 cases NKTCL,
from which 23 cases were extranasal, included 6 nodal
cases [44]. In another series of 66 patients with nodal
cytotoxic cell lymphomas, one had the classic NKTCL
phenotype [51]. In addition, cases of nodal lymphomas
with a typical NKTCL phenotype and T-cell receptor
(TCR) gamma (TCRG) gene rearrangements in germ-
line configuration were described as case reports [48,49].
However, in other cases, the tumor probably originates
from cytotoxic T-lymphocytes, as in the series of nodallymphoma with a typical NKTCL phenotype reported by
Takashi et al., from which 4 cases had clonal TCRG gene
rearrangements [52]. Nodal NKTCL have a poor prog-
nosis, most patients surviving for less than one year;
they usually affect the cervical lymph nodes and the his-
tology and phenotype are similar to those of extranodal
NKTCL.Aggressive NK-cell leukemia
Aggressive NK-cell leukemia is a very rare and extremely
aggressive neoplasm, also with a higher prevalence among
Asians [2,35,36,53-55]. Men and women are equally af-
fected and the disease usually manifest in the third or four
decades. Patients usually present extremely ill, with fever
and other systemic symptoms, hepatosplenomegaly, pan-
cytopenia and abnormal liver function. Serum levels of
lactic dehydrogenase (LDH) and Fas Ligand (FasL) are
often markedly increased. The hemophagocytic syndrome
is frequent at diagnosis or during the disease course,
resulting from uncontrolled monocyte/macrophage acti-
vation in response to cytokines produced by the neoplastic
NK-cells [56-61]. The natural disease course is fulminant,
with multiorgan failure and disseminated intravascular co-
agulation, death occurring usually within a few weeks [62].Clinical staging
The Ann-Arbor staging system, originally designed for
Hodgkin’s lymphoma, is used for clinical staging of the
NHL in general (Table 4) [63,64]. However, this system
is not completely satisfactory for NKTCL, as it does not
take into account the tumor size and the invasion to
contiguous structures, which may be important prognos-
tic features. Consequently, a modified tumor-staging sys-
tem originally proposed for sinonasal B-cell lymphoma
was adopted, which takes into account the local involve-
ment [65] (Table 4).
In order to perform disease staging, patients should be
evaluated with routine hematological and biochemical
analysis, bilateral bone marrow trephine biopsy, chest ra-
diography, computerized tomography, and digestive en-
doscopy. In addition, magnetic resonance imaging helps
to define the local involvement in nasal lymphoma, be-
ing superior to computerized tomography in determin-
ing the extent of soft-tissue infiltration, in differentiating
inflamed from neoplastic tissue, and in clarifying bone
lesions [66]. Positron emission tomography using fluorine-
18-fluoro-deoxy-glucose is useful to investigate systemic
spread and to distinguishing lymphoma from inflamma-
tory masses [67].
The ratio of patients presenting limited extranodal dis-
ease stages (IE or IIE) versus those with presenting with
advanced disease stages (III or IV) is 7:3 for nasal NKTCL
and 4:6 for extranasal NKTCL [36].
Table 4 Clinical staging systems used for aggressive NK-cell neoplasms
Staging system Stages Staging criteria [References]
Ann Arbor staging system*
Stage I Confined to one lymph node site-
[63,64]
Stage II
Confined to more than one lymph node site but
on one side of the diaphragm.
Stage III
Confined to lymphatic tissue or spleen but on
both sides of the diaphragm.
Stage IV
Bone marrow or liver involvement or extranodal
sites with widespread involvement.
Tumor staging used as a complement to the
Ann Arbor staging system for nasal NKTCL
T1 Confinement to the nasal cavity.
[65]
T2
Extension to the maxillary antra, anterior ethmoid
sinus or hard palate.
T3
Extension to posterior ethmoid sinus, sphenoidal sinus, orbit,
superior alveolar bone, cheeks, or superior buccinators space.
T4
Involvement of the inferior alveolar bone, inferior buccinators
space, infratemporal fossa, nasopharynx, or cranial fossa.
Abbreviations: NK natural-killer cells, NKTCL NK/T-cell Lymphoma, nasal type.
* Subscripts: A or B: absence (A) or presence (B) of constitutional symptoms; E: “extranodal” disease; X: largest tumor >10 cm large (“bulky disease”), or mediastinum
wider than 1/3 of the chest on a chest X-ray; S: spleen involvement. NKTCL are usually extranodal lymphomas; thus, the subscript E applies to the vast majority of cases.
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Histology and cytology
Natural killer/T cell lymphoma, nasal type, are histologi-
cally characterized by angiocentricity and invasion of the
blood vessels by lymphoma cells, resulting in ischemic
necrosis; the neoplastic cells have a variable size and
usually appear morphologically immature and the cyto-
logical features are heterogeneous, with a variable mix-
ture of inflammatory cells. Azurophilic granules are
usually observed in the cytoplasm of the lymphoma cells
using imprint smears [6]. Aggressive NK-cell leukemia
cells are larger than normal large granular lymphocytes
and often have a pale or slightly basophilic cytoplasm
with azurophilic granules and a nucleus with slightly im-
mature chromatin and inconspicuous or distinct nucle-
oli. As in NKTCL, necrosis, apoptosis, angioinvasion,
and angiodestruction are common findings in tissue bi-
opsies [6]. Also frequent is hemophagocytosis, which re-
sults from uncontrolled macrophage stimulation by
inflammatory cytokines produced by the neoplastic cells
and may result in the development of a hemophagocytic
syndrome.
Immunophenotype
Most of our knowledge on the immunophenotype of the
neoplastic NK-cells in NKTCL [30,35,37,50,68-70] as in
ANKCL [2,50,53-55,71-75], is based on immunohisto-
chemistry studies.
Like normal NK-cells, NKTCL and ANKCL tumor cells
do not express CD3 and the TCR on their surface [1].
Nevertheless, they often have the epsilon chain of CD3 in
the cytoplasm and, therefore, they may stain positively for
CD3 in immunohistochemistry of paraffin sections, impos-
ing the differential diagnosis with T-cell lymphoma [30].
Also as normal NK-cells, tumor NK-cells do not rearrangeTCR genes, which can be shown to be in germ-line
configuration by polymerase chain reaction (PCR) anal-
ysis. In addition, NKTCL and ANKCL tumor cells nearly
always express CD2 and less often CD7 and CD8, but
not CD4 and CD5. From the markers usually used to iden-
tify NK-cells, CD56 is the most frequently positive,
whereas CD16 expression is variable, and CD57 is almost
never found. In addition, cytotoxic granule–associated pro-
teins such as T-cell–restricted intracellular antigen (TIA-1),
granzyme B, and perforin are frequently expressed. The
immunophenotypic characteristics of NKTCL and ANKCL
cells seems to be similar, except for a higher frequency of
cyCD3epsilon+ and a lower frequency of CD16+ cases in
NKTCL [37].
Only a limited number of studies have evaluated the
expression of killer receptors on the neoplastic NK-cells
from patients with NKTCL and ANKCL [76-80]. Reverse
transcriptase PCR techniques, revealed that most NKTCL
tumor cells do express killer lectin type receptors (KLR)
transcripts, including those for the CD94 and the NKG2
(most frequently NKG2A/B and NKG2D) receptors [80],
a result that was confirmed by immunohistochemical
stainings on tissue biopsies [76,77] and flow cytometry
immunophenotyping of NKTCL and ANKCL cells [78].
The expression of killer immunoglobulin like receptors
(KIR) seems to be more variable [76-78].
Linker for activation of T cells (LAT), a membrane pro-
tein that plays an important role in T-cell activation, which
appears early during T-cell development and is present on
T- and NK-cells, among others, is expressed in the great
majority of T- and NK-cell neoplasms [81]. CD70, the re-
ceptor for CD27, was also found to be expressed both on
NK-cell lines and on NKTCL lymphoma cells [82].
Ki67 is also frequently positive and the percentage of
Ki67+ cells has proven to be a prognostic factor in
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as MKI67) is a nuclear marker strictly associated with cell
proliferation, which is present during all active phases of
the cell cycle (G1, S, G2, and mitosis), but is absent from
resting cells (G0) [84].
The fact that interactions between chemokines and
chemokine receptors are involved in migration of lym-
phoma cells and tissue invasion have lead to the investi-
gation of chemokine receptor expression on NKTCL
cells [69,70,74,75]. These studies revealed that NKTCL
cells usually express CXCR3, whose main ligand is
CXCL11 (IP9, IFN-gamma inducible protein type 9)
[68-70]. In addition, ANKL cells are simultaneously posi-
tive for CXCR1 and CCR5, whose major ligands are
CXCL1 (interleukin-8, IL-18) and the CCL3 (MIP-1alpha,
macrophage inflammatory protein type 1 alpha), CCL4
(MIP-1beta) and CCL5 (RANTES, regulated on activation,
normal T cell expressed and secreted) chemokines, re-
spectively [74,75].
Primary nodal NKTCL have the same phenotypic and
genotypic characteristics as extranodal NKTCL, at least
for the markers that are frequently tested, most of them
being described as being CD2+, sCD3-, cytCD3epsilon+,
CD56+, EBV+ and as having the TCR genes in germ-line
configuration; moreover, they also usually have a CD4-,
CD5-, CD7-, cytotoxic molecules+ phenotype [48,49,52].
In overall, the immunophenotypic features of the neo-
plastic NK-cells from patients with NKTCL and ANKCL
are different from those of normal peripheral blood NK-
cells [85], reactive NK-cells from patients with acute and
chronic NK-cell lymphocytosis associated with viral infec-
tions and tumors [86,87], and monoclonal CLPD-NK [88].
Chromosomal and genomic abnormalities
Cytogenetic analyses of the NK-cell neoplasms are diffi-
cult because of the scarcity of specimens, small-size
samples, tissue necrosis and the presence of inflamma-
tory cells. Despite these difficulties, several studies were
performed to date [89-96], some of them using com-
parative genomic hybridization and loss of heterozygos-
ity techniques. Currently, genetic abnormalities specific
for NKTCL and ANKL have not yet been identified, al-
though complex chromosomal aberrancies occur in a
large fraction of cases, abnormalities of the chromosome
6 being the most frequent finding [89]. In overall, cyto-
genetic aberrancies are seen in up to 77% of cases and
karyotypic abnormalities observed include pseudodiploidy
(57%), hyperdiploidy (30%), and hypodiploidy (13%) [89].
Recurrent abnormal chromosomal losses are 6q16–q25,
11q23.1, 11q24-q25, 13q14.11 and 17p13.3, among others;
chromosomal gains include 1q21–q44, 2q13-q14, 2q31.1–
q32.2, 6p25–p11.1, 7q11.2–q34, 7q35-q36 and 17q21.1
[89-96]. A common deletion on 6q in the target area
6q21-25 was identified, affecting multiple genes that areprobably involved in oncogenesis and disease progression
[90-96].
Concluding remarks
Mature NK cell neoplasms comprise a wide spectrum of
entities, from cases with an indolent disease course
(chronic NK-cell lymphocytosis) to cases with aggressive
clinical behavior (NKTCL and ANKCL). Aggressive NK-
cell neoplasms are EBV-related diseases with a particular
geographic distribution, have a typical immunophenotype
and complex karyotypic abnormalities, often affecting ex-
tranodal organs and tissues, invading and destroying the
adjacent structures, causing hemophagocytosis and dis-
seminating thought the body. Due to their rarity, they are
difficult to diagnose and to manage, and except for nasal
NKTCL in early stages, they are refractory to the available
therapies and have a very poor prognosis. Thus, multi-
centric registering studies and clinical trials are needed in
order to better understand the disease biology and to de-
velop new therapeutic agents.
Endnotes
a The estimated incidence of NHL varies worldwide,
with the highest rates being reported in the most eco-
nomically developed regions of the world (e.g. Northern
America, Australia/New Zealand, and Northern Europe)
and the lowest rates in the least developed regions (e.g.
South-Central and Eastern Asia, and the Caribbean).
According to data provided by the Cancer Research,
UK (http://www.cancerresearchuk.org/, accessed in 10
September 2011), the crude incidence rate in the UK in
2009 was 22 new NHL cases for every 100,000 males
and 18 for every 100,000 females and within the coun-
tries of the European Union, the highest age standard-
ized incidence rates for 2008 were estimated to be in
Luxembourg for men (around 19 cases per 100,000) and
Ireland for women (more than 13 cases per 100,000),
while the lowest rates were found in Greece for both
sexes (each around 3 cases per 100,000).
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